PT Brigit Biofarmaka Technologi Tbk (OBAT) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of PT Brigit Biofarmaka Technologi Tbk IDR 778, price IDR 218, upside +256.9%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PT Brigit Biofarmaka Technologi Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
21‑month range 193.00 IDR – 833.48 IDR · fair‑value band 363.17 IDR – 992.98 IDR · the 218.00 IDR price screens below the 778.11 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.
Follow PT Brigit Biofarmaka Technologi Tbk in your weekly email
Every Wednesday you see whether PT Brigit Biofarmaka Technologi Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Brigit Biofarmaka Technologi Tbk provides manufacturing services for herbal medicine, herbal honey, skincare, cosmetics, botanical tea, and functional powdered drinks in Indonesia.
Show more
PT Brigit Biofarmaka Technologi Tbk provides manufacturing services for herbal medicine, herbal honey, skincare, cosmetics, botanical tea, and functional powdered drinks in Indonesia. It also offers hair care products, including shampoo, conditioner, hair mask, hair tonic, hair oil, and hair serum and powder, as well as body moisturizer, body cleanser, facial cleanser, moisturizer, essence and serum, face mask, and personal care products. In addition, it provides lip gloss, cushion, foundation, eyeliner, and blush on balm. The company was founded in 2015 and is based in Sukoharjo, Indonesia.
Stock analysis
PT Brigit Biofarmaka Technologi Tbk (OBAT) currently trades at 218.00 IDR, while our model-based Fair Value estimate is 778.11 IDR, implying the stock looks roughly 72.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 1,753 IDR per share, and 19 of the 22 models we run sit above the 218.00 IDR price.
Bear case: the Asset-Based group reads lowest at 119.40 IDR, and 3 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: 363.17 IDR (bear) to 992.98 IDR (bull), the price of 218.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
PT Brigit Biofarmaka Technologi Tbk reported revenue of 160B IDR in FY2025 versus 56.9B IDR in FY2023, a compound +67.7%/yr. Reported net income was 22.6B IDR in FY2025, compounding +37.5%/yr from FY2023.
Key figures
Market cap 150B IDR (≈ $8.4M) · P/S ratio 0.86 · Dividend yield 8.9% · Net margin 14.1% · Return on equity 18.7% · Return on assets (EBIT) 40.8% · Operating margin 11.0% · Revenue (TTM) 175B IDR.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 58% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 9% fair-value upside, at 257%, OBAT screens cheaper than that median.
Fair Value models
Bear 363.17 IDRFair Value 778.11 IDRBull 992.98 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
Compare PT Brigit Biofarmaka Technologi Tbk with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 634 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PT Brigit Biofarmaka Technologi Tbk (OBAT) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of 778.11 IDR versus a price of 218.00 IDR, about +257% upside (undervalued).
What is the fair value of OBAT?
Our model-based fair value for PT Brigit Biofarmaka Technologi Tbk is 778.11 IDR (as of Sep 28, 2026), built from audited fundamentals. The current price: 218.00 IDR.
What is the quality score of OBAT?
PT Brigit Biofarmaka Technologi Tbk has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Our model-based price target is the fair value of 778.11 IDR (as of Sep 28, 2026) from 22 valuation models. Cautious scenario 363.17 IDR, optimistic scenario 992.98 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Brigit Biofarmaka Technologi Tbk stock forecast for 2026?
Our models put fair value at 778.11 IDR, about +257% upside versus a price of 218.00 IDR (undervalued). Cautious scenario 363.17 IDR, optimistic scenario 992.98 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
PT Brigit Biofarmaka Technologi Tbk reported trailing-twelve-month revenue of about 175B IDR (latest available figure, as of Sep 28, 2026).
Does PT Brigit Biofarmaka Technologi Tbk pay a dividend?
PT Brigit Biofarmaka Technologi Tbk currently shows a dividend yield of about 8.95% relative to its recent price (as of Sep 28, 2026).
What is the intrinsic value of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Brigit Biofarmaka Technologi Tbk it is 778.11 IDR per share (as of Sep 28, 2026), against a price of 218.00 IDR. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is PT Brigit Biofarmaka Technologi Tbk stock overvalued or undervalued in 2026?
As of Sep 28, 2026, OBAT trades below its calculated fair value: price 218.00 IDR, fair value 778.11 IDR, a gap of about +257% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OBAT?
No. The price is what the market pays today (218.00 IDR); the fair value is what the company's own numbers justify (778.11 IDR). For PT Brigit Biofarmaka Technologi Tbk the two are 560.11 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Brigit Biofarmaka Technologi Tbk worth?
The market values PT Brigit Biofarmaka Technologi Tbk at about 150B IDR (market capitalisation, as of Sep 28, 2026). Per share that is 218.00 IDR; our models calculate a fair value of 778.11 IDR per share.
What do the bullish and bearish scenarios say about OBAT?
Our models span a range for PT Brigit Biofarmaka Technologi Tbk: cautious scenario 363.17 IDR, base 778.11 IDR, optimistic 992.98 IDR per share (as of Sep 28, 2026, price 218.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Balance-sheet figures for PT Brigit Biofarmaka Technologi Tbk (as of Sep 28, 2026): return on equity 18.7%, debt of 0.05 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is OBAT from its 52-week high?
PT Brigit Biofarmaka Technologi Tbk trades at 218.00 IDR, about 58% below its 52-week high of 520.26 IDR and 13% above the low of 193.00 IDR (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 778.11 IDR is for.
Which stocks are comparable to PT Brigit Biofarmaka Technologi Tbk?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Brigit Biofarmaka Technologi Tbk stock attractive at the current price?
The data as of Sep 28, 2026: price 218.00 IDR, calculated fair value 778.11 IDR (+257%), Quality Score 59/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OBAT calculated?
We run PT Brigit Biofarmaka Technologi Tbk through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 778.11 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. PT Brigit Biofarmaka Technologi Tbk currently trades 72 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The closing price on Oct 2, 2026 was 218.00 IDR. Our model-based fair value is 778.11 IDR, about +257% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Brigit Biofarmaka Technologi Tbk right now?
The price is below even our cautious bear case (363.17 IDR). The market is more pessimistic than our downside scenario. The model range is unusually wide (363.17 IDR to 992.98 IDR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of PT Brigit Biofarmaka Technologi Tbk
How large is the market capitalisation of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The market capitalisation of PT Brigit Biofarmaka Technologi Tbk is 150B IDR (≈ $8.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The price-to-sales ratio of PT Brigit Biofarmaka Technologi Tbk is 0.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The dividend yield of PT Brigit Biofarmaka Technologi Tbk is 8.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The net margin of PT Brigit Biofarmaka Technologi Tbk is 14.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The return on equity (ROE) of PT Brigit Biofarmaka Technologi Tbk is 18.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
On an EBIT basis the return on assets of PT Brigit Biofarmaka Technologi Tbk is 40.8% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
The operating margin of PT Brigit Biofarmaka Technologi Tbk is 11.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Revenue at PT Brigit Biofarmaka Technologi Tbk is growing +51.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Brigit Biofarmaka Technologi Tbk (OBAT)?
Earnings per share at PT Brigit Biofarmaka Technologi Tbk are growing −56.6% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch PT Brigit Biofarmaka Technologi Tbk in the live analysis
One click puts PT Brigit Biofarmaka Technologi Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
